Research Article
[Retracted] Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C
Table 2
Distribution of patients with ALT <40 U/L at different time periods.
| Indicators (months) | Control group (n = 26) | Tenofovir group (n = 26) | Entecavir group (n = 26) |
| 3 | 7 (26.92%) | 15 (57.68%)#& | 12 (46.15%)# | 6 | 10 (38.46%)∗ | 20 (76.92%)∗#& | 17 (65.38%)∗# | 12 | 12 (46.15%)∗@ | 23 (88.46%)∗@#& | 20 (76.92%)∗@# |
|
|